GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Rising Biosciences Inc (GREY:RBII) » Definitions » Cash Flow from Financing

Rising Biosciences (Rising Biosciences) Cash Flow from Financing : $0.00 Mil (TTM As of . 20)


View and export this data going back to . Start your Free Trial

What is Rising Biosciences Cash Flow from Financing?

Cash from financing is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders.

For the three months ended in . 20, Rising Biosciences paid $0.00 Mil more to buy back shares than it received from issuing new shares. It received $0.00 Mil from issuing more debt. It paid $0.00 Mil more to buy back preferred shares than it received from issuing preferred shares. It received $0.00 Mil from paying cash dividends to shareholders. It received $0.00 Mil on other financial activities. In all, Rising Biosciences spent $0.00 Mil on financial activities for the three months ended in . 20.


Rising Biosciences Cash Flow from Financing Historical Data

The historical data trend for Rising Biosciences's Cash Flow from Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Rising Biosciences Cash Flow from Financing Chart

Rising Biosciences Annual Data
Trend
Cash Flow from Financing

Rising Biosciences Quarterly Data
Cash Flow from Financing

Rising Biosciences Cash Flow from Financing Calculation

This is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders. In the calculation of free cash flow, cash from financing is not calculated because it is not related to operating activities.

Rising Biosciences's Cash from Financing for the fiscal year that ended in . 20 is calculated as:

Rising Biosciences's Cash from Financing for the quarter that ended in . 20 is:


Cash Flow from Financing for the trailing twelve months (TTM) ended in . 20 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Rising Biosciences  (GREY:RBII) Cash Flow from Financing Explanation

Cash from financing contains six items:

1. Issuance of Stock:
A company may raise cash from issuing new shares. Issuance of stock represents the cash inflow from offering common stock, which is the additional capital contribution to the entity during the period.

Rising Biosciences's issuance of stock for the three months ended in . 20 was $0.00 Mil.

2. Repurchase of Stock:
A company may raise cash from issuing new shares. It can also use cash to buy back shares. Repurchase of stock represents the cash outflow to reacquire common stock during the period.

Rising Biosciences's repurchase of stock for the three months ended in . 20 was $0.00 Mil.

3. Net Issuance of Debt:
Net issuance of debt is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive.

Rising Biosciences's net issuance of debt for the three months ended in . 20 was $0.00 Mil. Rising Biosciences received $0.00 Mil from issuing more debt.

4. Net Issuance of Preferred Stock:
A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.

Rising Biosciences's net issuance of preferred for the three months ended in . 20 was $0.00 Mil. Rising Biosciences paid $0.00 Mil more to buy back preferred shares than it received from issuing preferred shares.

5. Cash Flow for Dividends:
Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.

Rising Biosciences's cash flow for dividends for the three months ended in . 20 was $0.00 Mil. Rising Biosciences received $0.00 Mil from paying cash dividends to shareholders.

6. Other Financing:
Money spent or earned by company from other financial activities.

Rising Biosciences's other financing for the three months ended in . 20 was $0.00 Mil. Rising Biosciences received $0.00 Mil on other financial activities.


Rising Biosciences Cash Flow from Financing Related Terms

Thank you for viewing the detailed overview of Rising Biosciences's Cash Flow from Financing provided by GuruFocus.com. Please click on the following links to see related term pages.


Rising Biosciences (Rising Biosciences) Business Description

Traded in Other Exchanges
N/A
Address
1180 Cleveland Road, Sandusky, OH, USA, 44870
Rising Biosciences Inc is a United States-based company engaged in research and development activities. It is focused on oral and topical cannabis and non-cannabis based pharmaceuticals. The company seeks to address the market demand for the treatment of the danger of opiates, whose long-term effects can include liver damage, addiction and brain damage due to hypoxia, resulting from respiratory depression, among other complications.

Rising Biosciences (Rising Biosciences) Headlines

From GuruFocus

PAOG Officially Appoints Karl Riedel as New CEO and President

By Marketwired Marketwired 02-11-2019

Rising Biosciences Set To Acquire All Assets from PAO Group

By Marketwired Marketwired 11-07-2018